Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 19INDUSTRY 9OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Surgical Procedures, Operative 2Dexamethasone 2temoporfin 1pomalidomide 1pembrolizumab 1nimotuzumab 1liposomal doxorubicin 1ledipasvir 1ibrutinib 1golimumab 1Vinorelbine 1Tomography, X-Ray Computed 1Thalidomide 1Sofosbuvir 1Rituximab 1Ribavirin 1Radiotherapy 1Radiation 1Paclitaxel 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Mitoxantrone 1Mastectomy 1Irinotecan 1Infliximab 1Immunotherapy, Adoptive 1Hematologic Tests 1Drug Therapy 1Docetaxel 1Diagnostic Imaging 1Dermoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Recurrence × Bendamustine Hydrochloride × Clear all
NCT02747732 2019-04-23

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Sheba Medical Center

Phase 2 Unknown
72 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡